Based on the PD-1/PD-L1 expression feature in CML cells and specific T cells for CML, blocking the PD-1/PD-L1 interaction may restore the function of CML-specific CTLs and represent a novel therapeutic approach for CML. Here, CD274 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.